Nuclear hormone receptors are exerting their effect on transcription by interacting with basal factors of the transcription machinery and/or by recruiting intermediary factors, such as the mouse protein GRIP1. GRIP1 is one of the recently identified coactivators for nuclear hormone receptors. Upon interaction with the hormone-binding domain of the receptors, GRIP1 increases their transcriptional activity. Here we show that GRIP1 contains at least two receptor-interacting regions using the hormone-binding domain of several receptors as bait in the yeast two-hybrid assay. GRIP1 interacts in a hormone-dependent manner with the C-termini of nuclear hormone receptors such as GRα, TRα, TRβ, RARα and RXRα but not with v-ErbA. GRIP1 contains several LXXLL motifs which were shown to be required for receptor interaction. A protein fragment containing all of the three LXXLL motifs, but having the activation domain deleted, is able to repress the transcriptional activity of human TRβ, whereas a region harbouring only one LXXLL motif fails to do so. A protein fragment with two LXXLL motifs exhibits an intermediate modulation of the TRβ transactivation. While one motif seems to be sufficient for receptor interaction, more than one motif is needed for functional interference.
INTRODUCTION
Nuclear hormone receptors represent a family of ligand dependent transcription factors. They have an influence on development, cell differentiation and physiology of higher eukaryotes, which points to an important role for multicellular organisms. All members are similarly structured, with a central DNA-binding domain (DBD), a C-terminus that harbours the hormone-binding domain (HBD) and the hormone-inducible transactivation domain 2 (AF2; 1-3).
The receptors for glucocorticoid (GR) and thyroid hormones (TR) belong to different subclasses. The steroid hormone receptor GR enters the nucleus upon hormone-binding and interacts as a homodimer with its responsive DNA-element (HRE). The non-steroid hormone receptor TR is localized in the nucleus, even in the absence of hormone. It binds as a homodimer or as a heterodimer complexed with RXR to HREs and actively silences the transcription of corresponding genes. For TR, an interaction with the corepressors N-CoR (4) or SMRT (5) has been shown. Upon ligand binding the corepressors dissociate from the receptor and coactivator-binding can occur. Thus, the transcriptional silencer TR is converted into an activating transcription factor (6) (7) (8) .
Recently several nuclear receptor-interacting factors have been characterized, for some of which it was shown, that they, compared with N-CoR and SMRT, bind to different sites on the receptor: SRC-1 (9), TIF1 (10), RIP140 (11) , GRIP170 (12), RIP160 (13) , CBP (14) , GRIP1 (15) and its human orthologue TIF2 (16) , GRIP120/hnRNP U (17), ARA 70 (18) , TRIP230 (19) and ACTR/RAC3 (20, 21) . For some of these intermediary factors it was shown that they represent coactivators. By definition, coactivators are able to contribute to transcriptional activation of DNA-bound transcription factors (22) (23) (24) .
GRIP1 (15, 25) and TIF2 (16) show 94% identity in the amino acid sequences. Both are widely expressed and are able to interact with the HBD of several nuclear hormone receptors. Immunostaining revealed that TIF2 is localized throughout the nucleus, predominantly in discrete bodies, with the nucleoli excluded (16) . While GRIP1 was examined mainly in yeast and found to enhance the activity of all receptors it interacts with (25), TIF2 was investigated in mammalian cells (16) . There, it influences only some of the receptors it interacts with. It is possible that yeast lacks an AF2-interacting coactivator (15) , since the AF2 activation domain of nuclear receptors does not function in yeast. Therefore, yeast provides an ideal system to characterize the interaction between receptors and their coactivators.
For SRC-1, RIP140 and TIF1 it has been shown that a peptide as small as 8-12 amino acids is able to interact with ER, RAR and RXR in a hormone dependent manner (26, 27) . These small regions contain the striking motif LXXLL. SRC-1 possesses seven receptor-interacting motifs (27) , while four of them were shown to be responsible for interaction with the receptors (27) . The two orthologue proteins GRIP1 and TIF2 contain in total only four of these motifs, for which we show that three in their central region are sufficient for binding.
We have analyzed the receptor-interacting regions of the mouse protein GRIP1 in yeast two-hybrid assays and in transiently *To whom correspondence should be addressed. Tel: +49 641 99 35460; Fax: +49 641 99 35469; Email: rainer.renkawitz@gen.bio.uni-giessen.de transfected mammalian cells. We can show that a part of GRIP1, containing all three LXXLL motifs, but lacking the transactivation domain, represses the transcriptional activity of TRβ. However, a construct containing only one LXXLL motif seems not to be sufficient in competing endogenous coactivators, whereas it is sufficient for hormone dependent binding.
MATERIALS AND METHODS

Plasmid construction
Yeast two-hybrid system. Expression plasmid for lexA (pEG202) and the reporter plasmid pSH18-34 were kindly provided by R.Brent (28) . The construction of the lexA-HBD fusions for TRα, TRβ, RARα and v-ErbA were kindly provided by D.Thormeyer. The lexA-RXRα fusion was described by Lee et al. (29) . To obtain lexA-GRα-HBD, the cDNA of the GR encompassing the amino acids 488-777 was derived from pRS hGR I488 (30) and subcloned in pBSK II -(Stratagene) using the BamHI and XhoI sites. The resulting plasmid was redigested with NotI, treated with Klenow and digested with XhoI. The insert was introduced in pEG202, treated with BamHI, Klenow and XhoI.
The expression plasmids for VP16-fusions were kindly provided in all three reading frames (p414GALNVP0, 1 or 2) by M.Funk (31) and the cDNA for the GRIP1 fragment 322-1121 by M.Stallcup (15) . A 2.5 kb EcoRI fragment of pGAD10.GRIP1 (15) was inserted into the EcoRI site of p414GALNVP0 resulting in construct A (GRIP1 amino acids 322-1121; Fig. 3B ). GRIP1-deletions: construct B (amino acids 322-765) was created by digesting construct A with XhoI and religation; construct C (amino acids 322-703) by digesting construct A with MscI and XhoI, followed by treatment with Klenow enzyme and religation; construct D (amino acids 322-543) by treatment with NcoI, XhoI and Klenow fragment and religation; construct E (amino acids 543-765) by inserting the NcoI-Klenow-XhoI fragment of GRIP1 into p414GALNVP1, treated with EcoRI-Klenow and XhoI; construct F (amino acids 543-703) was achieved by religation of construct E after treatment with MscI, XhoI and Klenow; construct G (amino acids 543-617) was obtained by insertion of the SphI-Vent-polymerase-BamHI treated fragment of GRIP1 into p414GALNVP1, which was treated with EcoRI, Klenow and BamHI; for generation of construct H (amino acids 765-1121) the C-terminal XhoI-Klenow-EcoRI fragment of GRIP1 was inserted into the BamHI-Klenow-EcoRI digested p414GALNVP2; to obtain construct I (amino acids 921-1121), the C-terminal BstEII-Klenow-XhoI fragment of construct A was inserted into p414GALNVP2 treated with BamHI, Klenow and XhoI; construct J (amino acids 703-1001) was made by inserting the MscI fragment of GRIP1 into the BamHI-Klenow treated p414GALNVP2; construct K (amino acids 703-765) was obtained by digestion of construct B with MscI and XhoI and ligation into p414GALNVP2, which was treated with BamHI, Klenow and XhoI; construct L (amino acids 728-765) was achieved by inserting the MaeIII-Klenow-XhoI fragment of GRIP1 into p414GALNVP1, EcoRI-Klenow-XhoI.
Mammalian system. pAB-Gal4 94 and pAB-Gal4 94 -hTRβ were described by Baniahmad et al. (32) and pAB-NLS by Busch et al. (33) . To express different parts of GRIP1, construct E ( Fig. 3B ) was treated with EcoRI, XhoI and Klenow or with EcoRI, MscI and Klenow and inserted into pAB-NLS treated with AccI and Klenow, yielding GRIP1 543-765 and GRIP1 543-703, respectively. To obtain expression of GRIP1 703-765, construct K ( Fig. 3B ) was digested with BamHI and XhoI, incubated with Klenow and inserted into pAB-NLS treated with PvuII. The reporter used, p17mer 6x tkCAT∆H/N, was described by Baniahmad et al. (8) .
Two-hybrid assays
Yeast-strain EGY 48 (MATα, his3, trp1, ura3-52, leu2::pLEU2-LexAop6) was kindly provided by R.Brent (28) . Yeast cells were transformed and selectively grown as described by Baniahmad et al. (34) . Two-hybrid assays were performed as described (34) . Hormones used are triamcinolone acetonide, 10 -5 M, triiodothyroacetic acid and retinoic acid, 10 -6 M. All hormones were obtained from Sigma, Heidelberg. Results presented are representative for at least three independent repetitions.
Cell culture and CAT assay
CV1 cells were cultured in DMEM-medium supplemented with 10% FCS and 5% PenStrep (Gibco) at 37_C, 5% CO 2 . Transient transfections were carried out using the calcium phosphate method (35, 36) with 0.3 pmol reporter, 0.03 pmol pAB-Gal4 94 or pAB-Gal4 94 -hTRβ and 5 pmol pAB-NLS or with coding sequences of the indicated fragments of GRIP1. Transfected CV1 cells were grown overnight in the presence of 10 -6 M T3 (Serva), harvested and lysed as described (37, 38) .
Immunoblotting
Yeast cultures were centrifuged and resuspended in SDS-loading buffer (10 mM Tris-Cl pH 6.8, 3% SDS, 5% β-mercaptoethanol, 20% glycerol, 0.6% bromphenolblue solution) to a density of 10 6 cells/µl. Extracts were separated on a 10% SDS gel and transferred to an Immobilon-membrane (Millipore). Immunoblotting was carried out using the ECL-system (Amersham) according to the manufactors protocol. The monoclonal antibody against the viral protein VP16 was kindly provided by P.Chambon and was used in a 1:500 dilution supplemented with 5% non-fat milk.
RESULTS
Hormone dependent interaction of GRIP1 with nuclear hormone receptors
The region of the mouse protein GRIP1 spanning the amino acids 322-1121 (15) was used to test for interaction with several nuclear hormone receptors. This fragment, when expressed as a lexA fusion, is able to transactivate a reporter gene (lacZ) controlled by eight lexA binding-sites, confirming previous results (15; data not shown). Since the N-terminal part of GR (amino acids 1-488) does not interact with GRIP1 (data not shown), we fused the hormone-binding domains (HBD) of several receptors to lexA for use as bait in a yeast two-hybrid assay. Yeast cells expressing VP16 fusions with GRIP1, as prey, were cotransformed with the lexA receptor fusions and the reporter plasmid. HBDs derived from various receptors show no transactivation by themselves and cannot interact with the viral activator protein VP16, as seen in Figure 1A and B. In the presence of the appropriate hormone, GRIP1 interacts with the HBDs of GRα, TRα, TRβ and RARα (Fig. 1A) . Without hormone there is no GRIP1 interaction detectable with neither the glucocorticoid nor the thyroid hormone receptors. The interaction with GR is weaker when compared with the other receptors (Fig.  1A) . RARα also binds to GRIP1 (amino acids 322-1211) but no significant hormone dependency can be detected, which is consistent with other publications (25) . Nevertheless, in experiments described below, the use of smaller GRIP1 fragments results in hormone-dependent binding. The oncogenic protein v-ErbA resembles a truncated TR with deletion of the AF2 activation domain and therefore lacks activation function (39) . This leads to a hormone-insensitive repressor (6) that is not supposed to interact with a transcriptional coactivator. As expected, GRIP1 fails to interact with v-ErbA.
Taken together, these results demonstrate that GRIP1 spanning amino acids 322-1121 is able to interact with several nuclear receptors, depending not only on the presence of hormone but also on the integrity of the AF2 activation domain of the receptors.
GRIP1 contains at least two receptor-interacting regions
Since the interaction domains of several receptors have been analyzed in detail (16, 25) , we focused our analysis on GRIP1. Therefore, we generated a series of deletions of GRIP1 as a prey and tested for interaction with each of the HBDs of TRα and GRα as bait. Figure 2A and B shows the results obtained with the tested deletions, while Figure 3B gives a schematic overview of GRIP1 deletions used.
In all cases the interaction of GRIP1 with TR is stronger than that obtained with GR, but both receptors interact with the same fragments of GRIP1. As seen in Figure 2A , the C-terminus (amino acids 765-1121, fragment H) of GRIP1 fails to interact although it contains a LXXLL motif. Similarly the N-terminal region (amino acids 322-543, fragment D) does not interact. We verified the expression of the VP16-GRIP1 constructs by immunoblotting with a monoclonal antibody against VP16, as indicated in Figure 2C . The expression of the largest receptorinteracting (residues 332-1121, fragment A) and non-interacting fragments (residues 765-1121, fragment H) of GRIP1 are shown. Additional bands are unspecific and appear in variable intensities.
The central GRIP1 domain clearly interacts with both receptors and can even be divided into two parts, ranging from amino acids 543 to 703 (F) and 703 to 765 (K). We termed these two parts receptor-interacting regions IR1 and IR2, respectively. IR1 contains two LXXLL motifs, while IR2 harbours only one motif (Fig. 3B) . The IR2 interaction domain can be further delineated to 37 amino acids (residues 728-765, fragment L). This construct still interacts, though weaker, hormone-dependently with GR and TR ( Fig. 2A and B) . The responsible area of IR1 could be indirectly further delineated to amino acids 617 and 703, since a fragment of GRIP1 ranging from amino acid 543 to 617 (G) does not interact with the TR (Fig. 2A) .
The N-terminal GRIP1 fragment spanning amino acids 322-765 (fragment B) that harbours all three LXXLL motifs does not transactivate a reporter gene (data not shown), but is able to interact with DNA-bound receptors. This leads to the conclusion that the receptor-interacting region is not coupled to the transactivation domain of GRIP1, which potentially enables the construction of dominant negative acting GRIP1 mutants.
Taken together, these results suggest that GRIP1 contains at least two receptor-interacting regions, one spanning 86 amino acids (residues 617-703), the other 37 amino acids (residues 728-765). Both regions can interact with either TR or GR, while the interaction with TR is stronger. Furthermore, the interacting region of GRIP1 can clearly be distinguished from the transactivation domain.
The two interacting regions of GRIP1 also bind to the HBDs of RXR and RAR
In a next step we analyzed the interaction of the two GRIP1 fragments IR1 and IR2 with the retinoic acid receptors RARα and RXRα in the yeast two-hybrid assay (Fig. 4) . In the presence of hormone the HBDs of each, RXR and RAR as bait, interact with both IRs of GRIP1 in a similar manner to that seen with the TR. While the longer GRIP1 fragment (amino acids 322-1121, Fig. 1 ) shows significant interaction with RAR even in the absence of ligand, both of the IRs of GRIP1 are strictly hormone-dependent (Fig. 4) . The mapped IRs seem to contain the domains that are necessary to interact with the nuclear hormone receptors in a hormone-dependent manner.
Influence of GRIP1 on the transactivation of TRβ in mammalian cells
To test the functional relevance of the interacting GRIP1 domains, we cotransfected CV1 cells with expression vectors for a Gal-DBD-hTRβ fusion (32) and constructs expressing GRIP1-fragments. Functional interaction domains of GRIP1 should compete for endogenous coactivator binding to TR and therefore should repress T3 mediated transactivation. The transcriptional activity of the human TR was measured in the presence of hormone with either the empty expression vector or with the GRIP1 constructs. The reporter gene used (CAT) was driven by the thymidine kinase promoter and six copies of the Gal4-binding site. As control, we also tested the influence of these GRIP1 constructs on the promoter activity itself by using only the DNA-binding domain of Gal4. Figure 5 shows that the three (Fig. 3B ). Hormones used: triamcinolone acetonide for GRα, triiodothyroacetic acid for TRα and retinoic acid for RXRα and RARα. GRIP1 fragments influence the basal transcription only weakly. However, the transcriptional activity of the ligand-bound TR is dramatically decreased upon coexpression of GRIP1 543-765. This fragment contains all three LXXLL motifs and is able to act dominant negatively, presumably by competing for endogenous coactivators. Splitting of GRIP1 543-765 into IR1 and IR2 shows that IR1 is able to reduce the transactivity of TR significantly. In contrast IR2 shows no influence (Fig. 5) .
Our results indicate that although one single LXXLL motif is able to bind to the liganded TR, it is not sufficient to influence the transactivity of the receptor.
DISCUSSION
The present work shows that the protein fragment of GRIP1 spanning the amino acids 322-1121 (15) contains at least two distinguishable interacting regions (IRs) for nuclear hormone receptors. These IRs are located in the center of the protein and encompass three LXXLL sequences, recently described as hormone receptor interaction motifs (26, 27) . We showed here for the first time that the central receptor-interacting region of GRIP1 can act dominant negatively when overexpressed in mammalian cells. Thereby we found that a fragment containing only one LXXLL motif (IR2) has no influence on the TR transactivity, but a fragment containing two LXXLL motifs (IR1) is sufficient. Nevertheless, the single tested LXXLL motif of IR2 enhances the dominant negative effect of IR1 in the fragment containing all three LXXLL motifs (Fig. 5 ). This could point to a functional synergy among the three LXXLL motifs. Yet, in yeast, the IR2 alone is sufficient for receptor binding.
Until now, the only dominant negative form of coactivators shown is the C-terminus of SRC-1 (amino acids 857-1061; 9,16), that contains one LXXLL motif. SRC-1, TIF2 and GRIP1 show a high degree of similarity and belong to a new class of nuclear hormone receptor coactivators (9, (14) (15) (16) 21) . A striking common feature is the well-conserved structure of these proteins (Fig. 3A) . The N-terminus harbours a basic helix-loop-helix motif (bHLH) and two PAS-domains (PAS-A and PAS-B), followed by a region rich in serines and threonines. In their central part they contain several LXXLL motifs, followed by a glutamine-rich region (21, 40) . The bHLH is originally defined to serve as a DNA-binding and dimerization motif. The existence of an as yet unidentified DNA sequence, to which the coactivators may bind, is unclear and not expected. The PAS-A and PAS-B domains represent a surface for protein-protein interactions. Although GRIP1 is comparable in structure to SRC-1, it lacks the C-terminal LXXLL motif (Fig. 3A) . Nothing has been known about the ability of the central LXXLL motifs to act as dominant negative molecules.
In the yeast two-hybrid assay all interactions observed between GRIP1 and GR were similar but weaker than those obtained with TR or the retinoic acid receptors. This could indicate either a lower stability of the expressed lexA-GR-HBD fusion or a weaker interaction. Nevertheless, we observed this phenomenon with all lexA-GR constructs (data not shown).
The failure of GRIP1 to interact with v-ErbA is likely to be due to both the missing AF2 activation domain and the hormone binding function. The integrity of the AF2 activation domain is critical for interaction with coactivators (16, 25) , though additional parts of the receptor are involved (41) . Since v-ErbA represents a truncated TR with mutation of the AF2 activation domain and lacks the activation function (6, 39) , an interaction with a coactivator was not expected. Therefore, the missing interaction confirms these expectations.
C-terminal of the identified IRs, GRIP1 contains an additional LXXLL motif around amino acid 878. This motif fails to interact with nuclear hormone receptors (Fig. 3B, fragment H) . Nevertheless, it may contribute to the interaction, since the GRIP1 fragment ranging from amino acid 703 to 1001 interacts more strongly with GR and TR than with IR2 (amino acids 703-765). It has been proposed that the LXXLL motifs should provide an α-helical secondary structure, with the conserved leucines forming a hydrophobic interface to be able to interact with the receptor AF2 activation domain. The amino acid directly N-terminal of the LXXLL motif should be preferentially hydrophobic. While the first leucine could, at least in some cases, be exchanged to valine, the presence of the other two leucines is absolutely required (27) . Since the three LXXLL motifs located in the central region of GRIP1 seem to fulfill these structural predictions, the fourth LXXLL motif contains a proline directly C-terminal of the two highly conserved leucines, which presumably disrupts the α-helical formation. Nevertheless, it may still be that this fourth LXXLL motif represents a cryptic interaction site for nuclear hormone receptors, perhaps stabilizing the interaction.
Both of the receptor-interacting fragments of GRIP1, IR1 and IR2, show no receptor preference when tested with TRα, TRβ, RARα and RXRβ in the yeast two-hybrid assay. This leads to the assumption that the interaction via the LXXLL motifs is a general mechanism for nuclear receptors and their coactivators.
The ability of one single LXXLL motif to bind to nuclear hormone receptors in the yeast two-hybrid assay and the inability of the same protein fragment to influence the transactivity of the TR in mammalian cells, could indicate that more than one binding motif is essential for proper binding and function. One isolated LXXLL motif is not sufficient to compete for coactivators that contain three binding motifs, as GRIP1, SRC-1 and TIF2 do. It
